Boston Scientific Corporation
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $119.32
- Today's High:
- $123.35
- Open Price:
- $119.7
- 52W Low:
- $92.8425
- 52W High:
- $129.12
- Prev. Close:
- $119.35
- Volume:
- 1885419
Company Statistics
- Market Cap.:
- $0
- Book Value:
- 12.417
- Revenue TTM:
- $13.05 billion
- Operating Margin TTM:
- 16.36%
- Gross Profit TTM:
- $8.68 billion
- Profit Margin:
- 6.92%
- Return on Assets TTM:
- 4.09%
- Return on Equity TTM:
- 5.18%
Company Profile
Boston Scientific Corporation had its IPO on under the ticker symbol BSX-PA.
The company operates in the Healthcare sector and Medical Devices industry. Boston Scientific Corporation has a staff strength of 45,000 employees.
Stock update
Shares of Boston Scientific Corporation opened at $119.7 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $119.32 - $123.35, and closed at $122.18.
This is a +2.37% increase from the previous day's closing price.
A total volume of 1,885,419 shares were traded at the close of the day’s session.
In the last one week, shares of Boston Scientific Corporation have slipped by -4.56%.
Boston Scientific Corporation's Key Ratios
Boston Scientific Corporation has a market cap of $0, indicating a price to book ratio of 0 and a price to sales ratio of 0.
In the last 12-months Boston Scientific Corporation’s revenue was $13.05 billion with a gross profit of $8.68 billion and an EBITDA of $3.28 billion. The EBITDA ratio measures Boston Scientific Corporation's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Boston Scientific Corporation’s operating margin was 16.36% while its return on assets stood at 4.09% with a return of equity of 5.18%.
In Q1, Boston Scientific Corporation’s quarterly earnings growth was a positive 210.8% while revenue growth was a positive 12%.
Boston Scientific Corporation’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 230.5283
- PEG
Its diluted EPS in the last 12-months stands at $0.53 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Boston Scientific Corporation’s profitability.
Boston Scientific Corporation stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0. Its price to sales ratio in the trailing 12-months stood at 0.
Boston Scientific Corporation stock pays annual dividends of $0 per share, indicating a yield of 5.02% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $32.89 billion
- Total Liabilities
- $4.08 billion
- Operating Cash Flow
- $0
- Capital Expenditure
- $111 million
- Dividend Payout Ratio
- 0%
Boston Scientific Corporation ended 2024 with $32.89 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $32.89 billion while shareholder equity stood at $17.85 billion.
Boston Scientific Corporation ended 2024 with $0 in deferred long-term liabilities, $4.08 billion in other current liabilities, 17000000.00 in common stock, $-450000000.00 in retained earnings and $13.27 billion in goodwill. Its cash balance stood at $570.00 million and cash and short-term investments were $570.00 million. The company’s total short-term debt was $510,000,000 while long-term debt stood at $0.
Boston Scientific Corporation’s total current assets stands at $5.70 billion while long-term investments were $0 and short-term investments were $0. Its net receivables were $2.08 billion compared to accounts payable of $868.00 million and inventory worth $2.05 billion.
In 2024, Boston Scientific Corporation's operating cash flow was $0 while its capital expenditure stood at $111 million.
Comparatively, Boston Scientific Corporation paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $122.18
- 52-Week High
- $129.12
- 52-Week Low
- $92.8425
- Analyst Target Price
- $
Boston Scientific Corporation stock is currently trading at $122.18 per share. It touched a 52-week high of $129.12 and a 52-week low of $129.12. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $122.56 and 200-day moving average was $111.68 The short ratio stood at 0.03 indicating a short percent outstanding of 0%.
Around 0% of the company’s stock are held by insiders while 9057.2% are held by institutions.
Frequently Asked Questions About Boston Scientific Corporation
Similar Industry Stocks (Medical Devices)
Most Active
Top Gainers
Top Losers
About
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through MedSurg and Cardiovascular segments. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, that uses in the treatment of coronary artery disease and aortic valve conditions. Further, it provides stents, balloon catheters, guidewires, atherectomy, and thrombectomy systems to treat arterial and venous diseases; and peripheral embolization devices, radioactive microspheres, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.